Emergent BioSolutions (EBS) Non-Current Assets (2010 - 2026)

Emergent BioSolutions' Non-Current Assets history runs 17 years deep, the most recent figure standing at $682.8 million for Q1 2026.

• On a quarterly basis, Non-Current Assets fell 5.07% year-over-year to $682.8 million in Q1 2026; TTM through Mar 2026 was $2.7 billion, a 14.91% decrease from a year earlier, with the FY2025 full-year figure at $656.1 million, down 17.05% from the prior year.
• Non-Current Assets improved to $682.8 million in Q1 2026 per EBS's latest filing, from $656.1 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $2.0 billion in Q4 2022 and bottomed at $656.1 million in Q4 2025.
• The 5-year median for Non-Current Assets is $1.1 billion (2024), against an average of $1.1 billion.
• Across the five-year window, Non-Current Assets increased 15.88% in 2022 and tumbled 41.53% in 2023, its largest moves.
• Year by year, Non-Current Assets stood at $2.0 billion in 2022, then tumbled by 41.53% to $1.1 billion in 2023, then tumbled by 30.84% to $791.0 million in 2024, then declined by 17.05% to $656.1 million in 2025, then grew by 4.07% to $682.8 million in 2026.
• Per Business Quant, the three latest EBS Non-Current Assets figures stand at $682.8 million (Q1 2026), $656.1 million (Q4 2025), and $674.1 million (Q3 2025).